Group 1 - Fuda Alloy's controlling shareholder Wang Dawu plans to reduce his stake by up to 3% of the company's total shares, amounting to a maximum of 406.34 million shares, due to personal funding needs [1] - ST Songfa's subsidiary signed contracts for the construction of 17 vessels, with a total contract value between 1.6 billion to 1.8 billion USD [2] - Pairui Co. signed a technical cooperation agreement with a university to develop large-capacity power semiconductor devices and related power electronic modules, effective for three years [3] Group 2 - Shuangliang Energy indirectly participates in commercial aerospace projects, supplying heat exchangers for SpaceX's fuel production system, with orders totaling approximately 1.39 million CNY [4] - Hangya Technology plans to issue convertible bonds to raise up to 600 million CNY for various projects, including an intelligent manufacturing base in Malaysia [5] - Yuhua Development is publicly selling assets with a base price of 251 million CNY for residential properties [6] Group 3 - Penghui Energy plans to invest 2.1 billion CNY in a new battery production project in Zhengyang County, Henan Province, focusing on high-performance battery products [7] - Haige Communication's shareholder Yang Haizhou intends to reduce his stake by up to 0.1624% of the company's total shares [8] - Yaoshi Technology's controlling shareholder pledged 5.13% of shares to repay loans, with a pledge period from February 10, 2026, to February 2, 2027 [9][10] Group 4 - Hanyu Pharmaceutical received FDA approval for its drug Acetate Glatiramer Injection, used for treating relapsing multiple sclerosis [11] - Baiyao Tai's GoliMab Injection received EMA approval for various indications, including rheumatoid arthritis and ulcerative colitis [12] - Jiangxi Tungsten Equipment plans to issue A-shares to raise up to 1.882 billion CNY for acquisitions [13] Group 5 - Hesong New Materials expects to recognize asset impairment provisions between 23.6 million to 28.5 million CNY for 2025 [14] - ST Meichen's subsidiary is involved in two major lawsuits with a total amount of approximately 31.9 million CNY [15] - China Coal Energy reported a 7.3% year-on-year decline in coal sales for January 2026, with total sales of 20.05 million tons [16] Group 6 - Yida Co. plans to adjust its epoxy propylene derivative project, reducing the total investment from 845 million CNY to 642 million CNY [17] - Fosun Pharma's subsidiary received approval for a clinical trial of HLX15-SC for multiple myeloma treatment [18][19] - Yinfeng Communication's board members and executives have terminated their share reduction plan [20] Group 7 - Huazhong High-tech has waived its preferential purchase rights for a fund, extending the investment period from three to four years [21] - Warner Pharmaceuticals plans to participate in a national drug procurement program, with expected sales of 176 million CNY [22] - Changling Hydraulic announced a tender offer to acquire 12% of its shares at a price of 35.82 CNY per share [23] Group 8 - ST Chuan Zhi's stock may face delisting due to financial data falling below regulatory thresholds [24] - Tian Pharmaceutical and its subsidiaries are participating in a national drug procurement program, with expected sales of 323 million CNY [25] - China Metallurgical Group signed new contracts worth 73.65 billion CNY in January 2026 [26] Group 9 - Torus plans to invest 21.2 million CNY in a venture capital fund focused on artificial intelligence [27] - Shangwei Co. received a government subsidy of 1.764 million CNY, representing 10.79% of its net profit for 2024 [28] - Hanghua Co. reported a 21.97% decline in net profit for 2025, with total revenue of 1.249 billion CNY [29] Group 10 - Huaxia Bank reported a 1.72% decline in net profit for 2025, with total revenue of 91.914 billion CNY [30] - Guotou Fengle plans to transfer 51% of its stake in Hubei Fengle Ecological Fertilizer to optimize management [31] - Huaru Technology is co-investing in a fund with a total commitment of 20 million CNY [32] Group 11 - Jindike reported a loss of 173 million CNY for 2025, despite a 40.13% increase in revenue [33] - Zhenong Co. announced a 0.52% increase in shares held by a major shareholder [34] - Maike Audi plans to recognize asset impairment provisions of approximately 52.55 million CNY [35] Group 12 - Fuan Pharmaceutical's subsidiary is expected to be selected for a national drug procurement program, with projected sales of 680 million CNY [36] - Rundu Co. is participating in a national drug procurement program, with some products expected to be selected [37] - Changqing Co. has postponed its large-scale die-casting project to March 2027 due to customer requirements [38] Group 13 - Pan Asia Micro透 received a patent for a graphene-based automotive headlight defogging device [39] - Luan An Huan Neng reported a 17.1% increase in raw coal production for January 2026, totaling 5 million tons [40] - Guangji Pharmaceutical received a drug registration certificate for Mecobalamin Tablets [41] Group 14 - Ruifeng New Materials announced the resignation of its deputy general manager for personal reasons [42] - Zhiguang Electric's subsidiary signed a procurement contract for energy storage equipment worth 210.4 million CNY [43] - Youyan Powder Materials reported a 19.41% increase in net profit for 2025 [44] Group 15 - Jincheng reported a 22.2% increase in net profit for 2025, with total revenue of 253 million CNY [46]

Group 1 - The company, Jiao Cheng Ultrasonic, announced the receipt of a government subsidy amounting to 10.4 million RMB, which is classified as a revenue-related government grant [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688392 证券简称：骄成超声 公告编号：2026-005 上海骄成超声波技术股份有限公司 关于获得政府补助的公告 公司根据《企业会计准则第 16 号——政府补助》等有关规定，确认上述事 项并划分补助类型。上述政府补助未经审计，具体的会计处理以及对公司损益的 影响最终以审计机构年度审计确认后的结果为准。敬请投资者注意投资风险。 特此公告。 上海骄成超声波技术股份有限公司董事会 2026 年 2 月 13 日 一、获得政府补助的基本情况 上海骄成超声波技术股份有限公司（以下简称"公司"）于近日收到政府补 助款项人民币 1,040 万元，属于与收益相关的政府补助。 二、补助的类型及对上市公司的影响 ...

Core Viewpoint - The China Securities 2000 ETF (563300) opened with a gain of 1.28%, priced at 1.500 yuan, indicating positive market sentiment towards small-cap stocks [1] Group 1: ETF Performance - The China Securities 2000 ETF (563300) has a performance benchmark based on the China Securities 2000 Index return [1] - Since its inception on September 6, 2023, the fund has achieved a return of 48.20% [1] - Over the past month, the fund has recorded a return of 5.40% [1] Group 2: Top Holdings Performance - Key stocks in the ETF include: - Ding Tong Technology, which rose by 3.78% [1] - Jiao Cheng Ultrasound, which increased by 1.90% [1] - Ping Tan Development, which fell by 0.26% [1] - Information Development, which gained 1.76% [1] - Chengdu Xian Dao, which rose by 2.18% [1] - Hua Rui Precision, which increased by 0.78% [1] - Ju Xin Technology, which gained 1.59% [1] - Dong Tian Wei, which rose by 3.17% [1] - Zhuo Yi Information, which increased by 4.48% [1] - Shen Gong Co., which rose by 2.72% [1]

Group 1 - The core point of the article is that Jiao Cheng Ultrasonic (688392.SH) has completed a share reduction plan, where Jianlin Management has reduced its holdings by 1.5735% of the company's total share capital, amounting to 1.821 million shares [1] Group 2 - The share reduction was executed through centralized bidding and block trading methods [1] - The reduction plan was fully implemented as of February 6, 2026 [1]

证券代码：688392 证券简称：骄成超声 公告编号：2026-004 上海骄成超声波技术股份有限公司 股东减持股份结果暨持股 5%以上股东持有权益比例降至 5%以下的权益变动提示性公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，上海骄成超声波技术股份有限公司（以下简称"公 司"）的股东上海鉴霖企业管理合伙企业（有限合伙）（以下简称"鉴霖企管"） 持有公司股份 7,587,584 股，占公司总股本的 6.56%，其中 6,467,542 股已于 2023 年 9 月 27 日起上市流通，1,120,042 股已于 2025 年 9 月 29 日起上市流通。以上 股份均来源于公司首次公开发行前及上市后资本公积转增股本取得的股份。 减持计划的实施结果情况 公司于 2026 年 1 月 8 日在上海证券交易所网站（www.sse.com.cn）披露了 《持股 5%以上股东减持股份计划公告》（公告编号：2026-002），因自身资金 需求，股东鉴霖企管拟于 ...

上海骄成超声波技术股份有限公司 简式权益变动报告书 上市公司名称：上海骄成超声波技术股份有限公司 股票上市地点：上海证券交易所 股票简称：骄成超声 股票代码：688392 信息披露义务人一：上海鉴霖企业管理合伙企业（有限合伙） 住所或通讯地址：上海市崇明区新海镇星村公路700号（上海新海经济 开发区） 信息披露义务人二：段忠福 住所或通讯地址：上海市闵行区 股份变动性质：股份减持，合计持股比例降至5%以下 签署日期：2026年2月6日 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国证券法》（以下简称 《证券法》）、《上市公司收购管理办法》（以下简称《收购管理办法》）、《公 开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》（以 下简称《准则 15 号》）等相关法律、法规和规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《证券法》《收购管理办法》及《准则 15 号》的规定，本报告书 已全面披露信息披露义务人在上海骄成超声波技术股份有限公司（以下简称"上 市公司"、"骄成超声"或"公司"）拥有权益的股份变动情况。 截至本报告书签署之日，除 ...

Group 1 - The core point of the announcement is that shareholders Shanghai Jianlin Enterprise Management Partnership (Limited Partnership) and their concerted action partner Duan Zhongfu reduced their holdings in the company by a total of 1.821 million shares, representing 1.5735% of the total share capital [1] - After the reduction, their combined shareholding decreased from 7.6076 million shares (6.5734%) to 5.7866 million shares (4.9999%), falling below the 5% threshold [1] - The reduction was driven by the funding needs of Jianlin Enterprise Management, and there are no plans for further increases in holdings over the next 12 months [1]

Core Viewpoint - The company, Jiao Cheng Ultrasonic, indicated that it does not expect to trigger mandatory performance forecast disclosures for the fiscal year 2025 based on preliminary calculations by its finance department and annual auditors [1] Group 1 - The company confirmed that its production and operations are currently normal [1] - The company will proceed with the preparation and disclosure of its 2025 annual report as required [1] - Investors are advised to await the official disclosure of the 2025 annual report for accurate financial data [1]

Group 1 - The core point of the article highlights the performance of the Zhongzheng 2000 ETF (563300), which opened with a gain of 1.17% at 1.472 yuan [1] - The top-performing stocks within the ETF include Ding Tong Technology, which rose by 2.53%, and Jiao Cheng Ultrasound, which increased by 1.85% [1] - The fund's performance benchmark is the Zhongzheng 2000 Index return, managed by Huatai-PB Fund Management Co., with a return of 45.49% since its establishment on September 6, 2023, and a monthly return of 6.52% [1]